MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.530
-0.140
-8.38%
After Hours: 1.600 +0.07 +4.58% 19:15 03/28 EDT
OPEN
1.660
PREV CLOSE
1.670
HIGH
1.730
LOW
1.500
VOLUME
442.69K
TURNOVER
0
52 WEEK HIGH
2.120
52 WEEK LOW
0.6501
MARKET CAP
114.32M
P/E (TTM)
-2.9110
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 1d ago
Weekly Report: what happened at CLSD last week (0318-0322)?
Weekly Report · 3d ago
Clearside Biomedical appoints Chong as CMO
Healthcare Clearside Biomedical appoints Chong as CMO on March 14, 2024. Dr. Victor Chong served most recently as VP, Global Head of Retina DAS at Johnson & Johnson Innovative Medicine. The company is a leader in the field of regenerative medicine.
Seeking Alpha · 03/18 17:56
Weekly Report: what happened at CLSD last week (0311-0315)?
Weekly Report · 03/18 09:56
12 Health Care Stocks Moving In Thursday's Intraday Session
Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. Aptorum Gr stock moved upwards by 43.65% to $6.22. Mira Pharmaceuticals stock rose by 17.27%.
Benzinga · 03/14 17:31
Clearside Biomedical Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:04
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga · 03/14 10:53
Clearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial Progress
TipRanks · 03/14 10:27
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Webull offers Clearside Biomedical Inc stock information, including NASDAQ: CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.